ONVO News and Press, Organovo Holdings Inc. From 04/15/24

A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 5.1% to $11.44 on volume of 198,678,404 shares Trio Petroleum Corp. (TPET) rose 22.1% to $0.63 on volume of 179,140,668 shares Soligenix Inc. (SNGX) rose 21.7% to $0.47 on volume of 133,754,026 shares Sup...

A look at the top 10 most actives in the United States Soligenix Inc. (SNGX) rose 127.5% to $0.8782 on volume of 62,157,057 shares Trio Petroleum Corp. (TPET) rose 8.0% to $0.5571 on volume of 48,902,033 shares Organovo Holdings Inc. (ONVO) rose 36.3% to $1.3769 on volume of 34,819,187 sh...

2024-04-15 09:05:46 ET DENVER, Colo., Apr 15, 2024 ( 247marketnews.com )- Organovo Holdings, Inc. (NASDAQ: ONVO ) reported complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treat...

2024-04-15 08:51:23 ET More on Organovo Holdings Financial information for Organovo Holdings Read the full article on Seeking Alpha For further details see: Organovo reports positive mid-stage results for FXR314 in metabolic dysfunction-associated steatohepatitis

SAN DIEGO, April 15, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today released the complete details of i...

2024-04-12 17:25:10 ET More on Organovo Holdings Financial information for Organovo Holdings Read the full article on Seeking Alpha For further details see: Organovo files to sell common stock, warrants

Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...

2024-01-26 17:15:37 ET More on Organovo Holdings Seeking Alpha’s Quant Rating on Organovo Holdings Historical earnings data for Organovo Holdings Financial information for Organovo Holdings Read the full article on Seeking Alpha For further det...

SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis, based on demonstration of clinical promise in three-dimensional (3D) human ti...

SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional ...